Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Oncogenomics
  • Published:

Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma

Abstract

To investigate the role of epigenetic gene silencing in the pathogenesis of Wilms' tumour and renal cell carcinoma (RCC), we determined their methylation profile using a candidate gene approach. Thus, 40 Wilms' tumours and up to 49 adult RCC were analysed by methylation-specific PCR for promoter methylation at CASP8, CDH1, CDH13, DAPK, MGMT, NORE1A, p14ARF and RARB2 in primary Wilms' tumours and CASP8, CDH1, CDH13, CRBP1, DAPK, MGMT, MT1G, NORE1A, p16INK4a, SDHB and RARB2 in primary RCC. Both tumour sample sets had previously been analysed for RASSF1A promoter methylation, and p16INK4a methylation results were also available for the Wilms' tumour samples. Wilms' tumours demonstrated a high incidence of methylation at CASP8 (43%) and MGMT (30%), intermediate frequencies at NORE1A (15%), p14ARF (15%), p16INK4a (10%), DAPK (11%) and CRBP1 (9%), but promoter methylation was rare or absent at RARB2 (0%), CDH13 (0%) and CDH1 (3%). No association was detected between methylation of RASSF1A, CASP8 or MGMT in individual tumours. The frequency of MGMT methylation was higher in stage 1 and 2 tumours (50%) than in stage 3 and 4 tumours (17%) but this did not reach statistical significance (P=0.06). RCC were most frequently methylated at DAPK (24%), MT1G (20%), NORE1A (19%), CDH1 (16%) and MGMT (9%) and not or rarely at SDHB (4%), RARB2 (0%), p16INK4a (0%) and CDH13 (3%). There were no associations between methylation of RASSF1A, DAPK and CDH1 in individual tumours. Papillary RCC demonstrated a higher frequency of DAPK methylation (43%) than clear cell tumours (19%) (P=0.14). We have demonstrated that de novo promoter methylation is frequent in Wilms' tumour and RCC, and these data enable methylation profiles to be constructed for each tumour type. Thus, combining our results with data published previously, it appears that promoter methylation occurs frequently (≥20% of primary tumours) at CASP8, SLIT2 and RASSF1A in Wilms' tumour and at RASSF1A, TIMP3, DAPK, SLIT2, MT1G and GSTP1 in RCC.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, Chauhan A, Walker R, Shaw JA, Hosoe S, Lerman MI, Minna JD, Maher ER and Latif F . (2001). Oncogene, 20, 1509–1518.

  • Arcellana-Panlilio MY, Egeler RM, Ujack E, Pinto A, Demetrick DJ, Robbins SM and Coppes MJ . (2000). Gene Chromosome Cancer, 29, 63–69.

  • Astuti D, Agathanggelou A, Honorio S, Dallol A, Martinsson T, Kogner P, Cummins C, Neumann HPH, Voutilainen R, Dahia P, Eng C, Maher ER and Latif F . (2001a). Oncogene, 20, 7573–7577.

  • Astuti D, Latif F, Dallol A, Dahia PL, Douglas F, George E, Skoldberg F, Husebye ES, Eng C and Maher ER . (2001b). Am. J. Hum. Genet., 69, 49–54.

  • Austruy E, Candon S, Henry I, Gyapay G, Tournade MF, Mannens M, Callen D, Junien C and Jeanpierre C . (1995). Gene Chromosome Cancer, 14, 285–294.

  • Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP . (1998). Adv. Cancer Res., 72, 141–196.

  • Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B, Randle D, Kondo M, Virmani A, Bader S, Sekido Y, Latif F, Milchgrub S, Toyooka S, Gazdar AF, Lerman MI, Zabarovsky E, White M and Minna JD . (2001). J. Natl. Cancer Inst., 93, 691–699.

  • Burrow CR . (2000). Exp. Nephrol., 8, 219–225.

  • Caca K, Feisthammel J, Klee K, Tannapfel A, Witzigmann H, Wittekind C, Mossner J and Berr F . (2002). Int. J. Cancer, 97, 481–488.

  • Clifford SC, Prowse AH, Affara NA, Buys CHCM and Maher ER . (1998). Gene Chromosome Cancer, 22, 200–209.

  • Costello JF and Plass C . (2001). J. Med. Genet., 38, 285–303.

  • Cote S, Sinnett D and Momparler RL . (1998). Anticancer Drugs, 9, 743–750.

  • Dallol A, Da Silva NF, Viacava P, Minna JD, Bieche I, Maher ER and Latif F . (2002). Cancer Res., 62, 5874–5880.

  • Dallol A, Morton D, Maher ER and Latif F . (2003). Cancer Res., 63, 1054–1058.

  • Dammann R, Li C, Yoon JH, Chin PL, Bates S and Pfeifer GP . (2000). Nat. Genet., 25, 315–319.

  • Dammann R, Takahashi T and Pfeifer GP . (2001a). Oncogene, 20, 3563–3567.

  • Dammann R, Yang G and Pfeifer GP . (2001b). Cancer Res., 61, 3105–3109.

  • Dreijerink K, Braga E, Kuzmin I, Geil L, Duh FM, Angeloni D, Zbar B, Lerman MI, Stanbridge EJ, Minna JD, Protopopov A, Li J, Kashuba V, Klein G and Zabarovsky ER. (2001). Proc. Natl. Acad. Sci., USA, 98, 7504–7509.

  • Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N and Brodeur GM . (2001). Cancer Res., 61, 1314–1319.

  • Esteller M, Cora PG, Baylin SB and Herman JG . (2001). Cancer Res., 61, 3225–3229.

  • Esteller M, Guo M, Moreno V, Peinado MA, Capella G, Galm O, Baylin SB and Herman JG . (2002). Cancer Res., 62, 5902–5905.

  • Esteller M, Hamilton SR, Burger PC, Baylin SB and Herman JG . (1999). Cancer Res., 59, 793–797.

  • Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB and Herman JG . (2000). Cancer Res., 60, 129–133.

  • Foster K, Prowse A, van den Berg A, Fleming S, Hulsbeek MMF, Crossey PA, Richards FM, Cairns P, Affara NA, Ferguson-Smith MA, Buys CHCM and Maher ER . (1994). Hum. Mol. Genet., 3, 2169–2173.

  • Gimenez-Roqueplo AP, Favier J, Rustin P, Rieubland C, Kerlan V, Plouin PF, Rotig A and Jeunemaitre X . (2002). J. Clin. Endocrinol., 87, 4771–4774.

  • Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM and Jones PA . (1995). Cancer Res., 55, 4531–4535.

  • Grotzer MA, Eggert A, Zuzak TJ, Janss AJ, Marwaha S, Wiewrodt BR, Ikegaki N, Brodeur GM and Phillips PC . (2000). Oncogene, 19, 4604–4610.

  • Grundy P, Telzerow P, Moksness J and Breslow NE . (1996). Med. Pediatr. Oncol., 27, 429–433.

  • Grundy RG, Pritchard J, Scambler P and Cowell JK . (1998). Br. J. Cancer, 78, 1181–1187.

  • Harada K, Toyooka S, Maitra A, Maruyama R, Toyooka KO, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Minna JD and Gazdar AF . (2002a). Oncogene, 21, 4345–4349.

  • Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, Malta H, Miyajima K, Timmons CF, Tomlinson GE, Mastrangelo D, Hay RJ, Chaudhary PM and Gazdar AF . (2002b). Cancer Res., 62, 5897–5901.

  • Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB . (1996). Proc. Natl. Acad. Sci. USA, 93, 9821–9826.

  • Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR and Linehan WM . (1994). Proc. Natl. Acad. Sci. USA, 91, 9700–9704.

  • Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D and Baylin SB . (1995). Cancer Res., 55, 4525–4530.

  • Hesson L, Dallol A, Minna JD, Maher ER and Latif F . (2003). Oncogene, 22, 947–954.

  • Huang Y, de la Chapelle A and Pellegata NS . (2003). Int. J. Cancer, 104, 735–744.

  • Huebner K . (2001). Proc. Natl. Acad. Sci. USA, 98, 14763–14765.

  • Jones PA . (1999). Trends Genet., 15, 34–37.

  • Kawakami M, Staub J, Cliby W, Hartmann L, Smith DI and Shridhar V . (1999). Int. J. Oncol., 15, 715–720.

  • Keller G, Vogelsang H, Becker I, Hutter J, Ott K, Candidus S, Grundei T, Becker KF, Mueller J, Siewert JR and Hofler H . (1999). Am. J. Pathol., 155, 337–342.

  • Klamt B, Schulze M, Thate C, Mares J, Goetz P, Kodet R, Scheurlen W, Weirich A, Graf N and Gessler M . (1998). Gene Chromosome Cancer, 22, 287–294.

  • Lee S and Haber DA . (2001). Exp. Cell Res., 264, 74–99.

  • Lee SW . (1996). Nat. Med., 2, 776–782.

  • Lo KW, Kwong J, Hui ABY, Chan SYY, To KF, Chan SC, Chow LSN, Teo PML, Johnson PJ and Huang DP . (2001). Cancer Res., 61, 3877–3881.

  • Maruyama R, Toyooka S, Toyooka KO, Virmani AK, Zochbauer-Muller S, Farinas AJ, Minna JD, McConnell J, Frenkel EP and Gazdar AF . (2002). Clin. Cancer Res., 8, 514–519.

  • Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and Ratcliffe PJ . (1999). Nature, 399, 271–275.

  • Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger, PC, Baylin SB and Sidransky D . (1995). Nat. Med., 1, 686–692.

  • Morrissey C, Martinez A, Zatyka M, Agathanggelou A, Honorio S, Astuti D, Morgan NV, Moch H, Richards FM, Kishida T, Yao M, Schraml P, Latif F and Maher ER . (2001). Cancer Res., 61, 7277–7281.

  • Nguyen A, Jing Z, Mahoney PS, Davis R, Sikka SC, Agrawal KC and Abdel-Mageed AB . (2000). Cancer Lett., 160, 133–140.

  • Nojima D, Nakajima K, Li LC, Franks J, Ribeiro L, Ishii N and Dahiya R . (2001). Mol. Carcinogen., 32, 19–27.

  • Richards FM, McKee SA, Rajpar MH, Cole TRP, Evans DGR, Jankowski JA, McKeown C, Sanders DSA and Maher ER . (1999). Hum. Mol. Genet., 8, 607–610.

  • Robertson KD and Jones PA . (1998). Mol. Cell Biol., 18, 6457–6473.

  • Sato M, Mori Y, Sakurada A, Fujimura S and Horii A . (1998). Hum. Genet., 103, 96–101.

  • Schulz S, Becker KF, Braungart E, Reichmuth C, Klamt B, Becker I, Atkinson M, Gessler M and Hofler H . (2000). J. Pathol., 191, 162–169.

  • Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, Cunningham HT, Reddy JL, Brambilla E, Takahashi T, Minna JD, Chaudhary PM and Gazdar AF . (2002). Cancer Biol. Ther., 1, 65–69.

  • Skotnicka-Klonowicz G, Rieske P, Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P and Debiec-Rychter M . (2000). Eur. J. Surg. Oncol., 26, 61–66.

  • Steenman MJ, Rainier S, Dobry CJ, Grundy P, Horon IL and Feinberg AP . (1994). Nat. Genet., 7, 433–439.

  • Storkel S and Vandenberg E . (1995). World J. Urol., 13, 153–158.

  • Taniguchi T, Sullivan MJ, Ogawa O and Reeve AE . (1995). Proc. Natl. Acad. Sci. USA, 92, 2159–2163.

  • Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, Behm FG, Look AT, Lahti JM and Kidd VJ . (2000). Nat. Med., 6, 529–535.

  • Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, Leigh I, Gorman P, Lamlum H, Rahman S, Roylance RR, Olpin S, Bevan S, Barker K, Hearle N, Houlston RS, Kiuru M, Lehtonen R, Karhu A, Vilkki S, Laiho P, Eklund C, Vierimaa O, Aittomaki K, Hietala M, Sistonen P, Paetau A, Salovaara R, Herva R, Launonen V and Aaltonen LA . (2002). Nat. Genet., 30, 406–410.

  • Toyooka S, Toyooka KO, Harada K, Miyajima K, Makarla P, Sathyanarayana UG, Yin J, Sato F, Shivapurkar N, Meltzer SJ and Gazdar AF . (2002b). Cancer Res., 62, 3382–3386.

  • Toyota M, Ahuja N, Ohe-Toyota M, Herman JG, Baylin SB and Issa JP . (1999). Proc. Natl. Acad. Sci. USA, 96, 8681–8686.

  • Toyooka KO, Toyooka S, Maitra A, Feng Q, Kiviat NC, Smith A, Minna JD, Ashfaq R and Gazdar AF . (2002a). Am. J. Pathol., 161, 629–634.

  • Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, Minna JD and Gazdar AF . (2001). Cancer Res., 61, 4556–4560.

  • Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D and Harris AL . (2002). Cancer Res., 62, 2957–2961.

  • Tycko B . (2000). J. Clin. Invest., 105, 401–407.

  • van der Velden PA, Metzelaar-Blok JAW, Bergman W, Hurks HMH, Frants RR, Gruis NA and Jager MJ . (2001). Cancer Res., 61, 5303–5306.

  • van Engeland M, Roemen GM, Brink M, Pachen MM, Weijenberg MP, de Bruine AP, Arends JW, van den Brandt PA, de Goeij AF and Herman JG . (2002). Oncogene, 21, 3792–3795.

  • Virmani AK, Rathi A, Zochbauer-Muller S, Sacchi N, Fukuyama Y, Bryant D, Maitra A, Heda S, Fong KM, Thunnissen F, Minna JD and Gazdar AF . (2000). J. Natl. Cancer Inst., 92, 1303–1307.

  • Wagner KJ, Cooper WN, Grundy RG, Caldwell G, Jones C, Wadey RB, Morton D, Schofield PN, Reik W, Latif F and Maher ER . (2002). Oncogene, 21, 7277–7282.

  • Wheeler JM, Kim HC, Efstathiou JA, Ilyas M, Mortensen NJ and Bodmer WF . (2001). Gut, 48, 367–371.

  • Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ and Sidransky D . (2002). Cancer Cell, 2, 485–495.

  • Yoon JH, Dammann R and Pfeifer GP . (2001). Int. J. Cancer, 94, 212–217.

  • Zbar B . (2000). Semin. Cancer Biol., 10, 313–318.

  • Zochbauer-Muller S, Fong KM, Virmani AK, Geradts J, Gazdar AF and Minna JD . (2001). Cancer Res., 61, 249–255.

  • Zuzak TJ, Steinhoff DF, Sutton LN, Phillips PC, Eggert A and Grotzer MA . (2002). Eur. J. Cancer, 38, 83–91.

Download references

Acknowledgements

We thank the Cancer Research UK, Association for International Cancer Research and West Midlands NHS Executive for financial support.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Eamonn R Maher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Morris, M., Hesson, L., Wagner, K. et al. Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma. Oncogene 22, 6794–6801 (2003). https://doi.org/10.1038/sj.onc.1206914

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1206914

Keywords

This article is cited by

Search

Quick links